Skip to main content

Table 5 Grade ≥ 3 hematological and non-hematological adverse events

From: Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

Toxicity

A

B

C

D

E

F

G

H

I

J

K

(Grade ≥ 3)

Tax

Cap

Bev + Tax

Bev + Cap

Bev + Exm

Mot + Tax

Bev + Tax+Cap

Bev + Cap+Cyc

Bev + Cap+Vin

Bev + Tax+Exr

Bev + Tax+Tre

Total n

351

47

1462

918

58

92

357

74

295

55

55

 

n1/n2

%

n1/n2

%

n1/n2

%

n1/n2

%

n1/n2

%

n1/n2

%

n1/n2

%

n1/n2

%

n1/n2

%

n1/n2

%

n1/n2

%

Hematologic

  

NA

NA

          

NA

NA

      

 Anemia

6/231

2.6

  

22/918

2.4

8/851

0.9

0/58

0.0

  

5/357

1.4

    

6/55

10.9

  

 Leukopenia

10/231

4.3

  

84/1145

7.3

3/851

0.4

0/58

0.0

  

37/357

10.4

  

32/295

10.8

    

 Neutropenia

37/262

14.1

  

267/1366

19.5

13/851

1.5

0/58

0.0

  

64/357

17.9

  

57/295

19.3

11/55

20.0

18/55

32.7

Non-hematologic

  

NA

NA

          

NA

NA

      

 Hypertension

11/351

3.1

  

133/1462

9.1

55/851

6.5

25/58

43.1

11/92

12.0

39/357

10.9

  

9/295

3.1

2/55

3.6

18/55

32.7

 Haemorrhage/bleeding

2/262

0.8

  

7/624

1.1

3/297

1.0

0/58

0.0

  

5/246

2.0

  

3/295

1.0

1/55

1.8

  

 Thromboembolic events

3/262

1.1

  

17/742

2.3

18/297

6.1

1/58

1.7

  

28/357

7.8

  

31/295

10.5

  

5/55

9.1

 Neuropathy

16/320

5.0

  

156/1448

10.8

3/851

0.4

0/58

0.0

10/92

10.9

19/357

5.3

  

11/295

3.7

6/55

10.9

20/55

36.4

 Nausea/vomiting

7/320

2.2

  

28/956

2.9

12/574

2.1

0/58

0.0

18/92

19.6

8/155

5.2

  

19/295

6.4

3/55

5.5

4/55

7.3

 Diarrhea

9/320

2.8

  

36/1164

3.1

29/574

5.1

0/58

0.0

3/92

3.3

21/357

5.9

  

10/295

3.4

3/55

5.5

4/55

7.3

 Mucositis/stomatitis

2/320

0.6

  

25/763

3.3

8/297

2.7

0/58

0.0

1/92

1.1

20/357

5.6

  

8/295

2.7

8/55

14.5

  

 Edema

6/231

2.6

  

4/420

1.0

  

0/58

0.0

          

2/55

3.6

 Proteinuria

1/262

0.4

  

14/565

2.5

3/297

1.0

    

18/246

7.3

  

1/295

0.3

4/55

7.3

  

 Hepatobiliary disorders

3/89

3.4

  

6/213

2.8

  

4/58

6.9

7/92

7.6

        

0/55

0.0

 Hand-foot syndrome

    

4/648

0.6

157/851

18.4

    

107/357

30.0

  

43/295

14.6

    

 Fatigue

20/320

6.3

  

59/1164

5.1

10/574

1.7

3/58

5.2

11/92

12.0

22/357

6.2

  

19/295

6.4

8/55

14.5

5/55

9.1

 Pain

11/320

3.4

  

22/989

2.2

9/277

3.2

2/58

3.4

9/92

9.8

4/246

1.6

    

1/55

1.8

0/55

0.0

 Alopecia

9/320

2.8

  

13/685

1.9

0/277

0.0

0/58

0.0

0/92

0.0

        

4/55

7.3

 Infection

10/320

3.1

  

19/615

3.1

27/297

9.1

  

9/92

9.8

16/266

6.0

  

37/295

12.5

    
  1. A = Tax, B = Cap, C = Bev + Tax, D = Bev + Cap, E = Bev + Exm, F = Mot + Tax, G = Bev + Tax+Cap, H = Bev + Cap+Cyc, I = Bev + Cap+Vin, J = Bev + Tax+ Eve, K = Bev + Tax+Tre
  2. Bev bevacizumab, Cap capecitabine, Tax taxanes, Vin vinorelbine, Cyc cyclophosphamide, Exm exemestane, Eve everolimus, Tre trebananib, Mot motesanib, NA not applicable, Total n number of all patients with regimens, n1/n2 the number of patients with adverse reactions / total enrolled patients
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us